Skip to main content

AgomAb Therapeutics NV

AGMB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0002020932

In the last 90 days, AgomAb Therapeutics NV insiders filed 7 open-market purchases and 0 sales; 34 institutions reported holding it in 13F filings for Q2 2026, worth $337.0M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by AgomAb Therapeutics NV insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
7 filings
3 insiders, $592.1K in total
Open-market sells
0 filings
Insiders trading
3
Net value
+$592.1K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for AgomAb Therapeutics NV, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for AgomAb Therapeutics NV
NameTitleLast reported holdingLast filingFilings, past year
Epstein David RDirector54,980Nov 16, 20265
Kemula Pierre Thadee VictorChief Financial Officer10,000Oct 7, 20261
Knotnerus Tim JasperChief Executive Officer21,823Oct 7, 20261
Garcia MarinoDirector–Sep 15, 20261
Patel NaimishDirector–Sep 15, 20261

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 16, 2026 (view filing)6:43 AM ETNov 133 daysEpstein David RDirectorPPurchase+15.0K$5.92+$88.7K+37.5%55.0K after4 lots
Nov 6, 2026 (view filing)6:39 AM ETNov 51 dayEpstein David RDirectorPPurchase+15.0K$6.90+$103.5K+60.0%40.0K after3 lots
Oct 22, 2026 (view filing)8:14 AM ETOct 211 dayEpstein David RDirectorPPurchase+10.0K$8.88+$88.8K+66.7%25.0K after2 lots
Oct 9, 2026 (view filing)8:01 AM ETOct 81 dayEpstein David RDirectorPPurchase+5.00K$8.90+$44.5K+50.0%15.0K after
Oct 7, 2026 (view filing)8:57 AM ETOct 5-62 daysEpstein David RDirectorPPurchase+10.0K$8.64+$86.3KNew position10.0K after2 lots
Oct 7, 2026 (view filing)8:47 AM ETOct 61 dayKemula Pierre Thadee VictorChief Financial OfficerPPurchase+10.0K$8.59+$85.9KNew position10.0K after3 lots
Oct 7, 2026 (view filing)8:06 AM ETOct 5-62 daysKnotnerus Tim JasperChief Executive OfficerPPurchase+11.0K$8.58+$94.4K+101.6%21.8K after2 lots